DBPR108是新型、具有口服活性、选择性的DPP4抑制剂，IC50=为15nM，对DPP8和DPP9基本无抑制。

DBPR108 is an orally bioavailable dipeptide-derived DPP4 inhibitor (IC50: 15 nM) and it has no inhibition on DDP8 and DPP9.

DBPR108 displays a more than 3000-fold selectivity over DPP8 DPP9, FAP and DPP-II.

DBPR108 is a potent, selective, long-acting and safe DPP-IV inhibitor as a potential treatment of type 2 diabetes mellitus. The in vivo effects of DBPR108, including inhibition of plasma DPP-IV activity and suppression of blood glucose elevation, were also demonstrated.

1186426-66-3

C16H25FN4O2

324.39

DMSO:≥ 25 mg/mL (77.07 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years